Clinical Research Directory

Inclusion Criteria: 1. Adults aged 30-70 years. 2. Prediabetes defined by any of the following: 3. Fasting Plasma Glucose (FPG) of 100-125 mg/dL, or 4. Glycated hemoglobin (HbA1c) of 5.7%-6.4%. 5. Willingness to provide written informed consent and comply with study procedures. Exclusion Criteria: 1. Established type 1 or type 2 diabetes mellitus, or recent use of oral antidiabetic agents or insulin (within 3 months). 2. Abnormal liver function, defined as Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) exceeding 2-fold the upper reference limit (≥2 × ULN) at screening. 3. Abnormal renal function, defined as serum creatinine (Cr) \>1.5 mg/dL or Estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.73 m². 4. Gastrointestinal disorders that may affect drug absorption, such as gastrostomy, enterostomy, severe chronic diarrhea, or malabsorption syndrome. 5. Severe comorbidities within the past 6 months, including major stroke, myocardial infarction, major trauma, or major surgery. 6. Recent use of medications (within 1 month) that may significantly alter blood glucose or lipids, such as systemic corticosteroids or non-stable doses of lipid-lowering agents. 7. Malignant tumor under active treatment, or immunodeficiency/autoimmune disorders requiring immunosuppressive therapy. 8. Psychiatric disorders or cognitive impairment that may affect protocol compliance. 9. Active use of other investigational drugs within 3 months prior to screening. 10. Pregnancy or lactation.